This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
WILDING, GEORGE
| Item Type | Name |
|
Academic Article
|
Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
|
|
Concept
|
Area Under Curve
|
|
Academic Article
|
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
|
|
Academic Article
|
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
|
|
Academic Article
|
Phase I trial of perillyl alcohol administered four times daily continuously.
|
|
Academic Article
|
Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor.
|
|
Academic Article
|
A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer.
|
|
Academic Article
|
Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion.
|
|
Academic Article
|
Phase I study of docetaxel and topotecan in patients with advanced malignancies.
|
|
Academic Article
|
Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
|
|
Academic Article
|
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
|
|
Academic Article
|
Motility of the antroduodenum in healthy and gastroparetics characterized by wireless motility capsule.
|
|
Academic Article
|
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors.
|
|
Academic Article
|
A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.
|